Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (4603)	6/29/1998 4:01:00 PM
From: Izzy	Read Replies (1) of 6136

Rick, I would agree with your proposed treatment regimen altho' HAART therapy, including the use of a PI, appears to be more of the current standard treatment approach. The article you posted was dated June 29 and gave results of combo treatment with Crixivan. Today, there is to be results on the combination of Sustiva with Viracept; I can't find the data yet. If Sustiva decreases Crixivan levels, but increases Viracept levels, it would seem to me that Viracept would again be the PI of choice. In fact, I still can't figure out why Crixivan is still be used, even in ongoing clinical trials. But, I guess, that's one of the purposes of having an AIDS conference; comparison of various treatment regimens. Thanks for your input today.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next